Artículos por temáticas

A novel form of necrosis, TRIAD, occurs in human Huntington's disease.

Yamanishi E, Hasegawa K, Fujita K, Ichinose S, Yagishita S, Murata M, Tagawa K, Akashi T, Eishi Y, Okazawa H.

Acta Neuropathol Commun. 2017 Mar 8;5(1):19. doi: 10.1186/s40478-017-0420-1.

Haplotype-based stratification of Huntington's disease.

Chao MJ, Gillis T, Atwal RS, Mysore JS, Arjomand J, Harold D, Holmans P, Jones L, Orth M, Myers RH, Kwak S, Wheeler VC, MacDonald ME, Gusella JF, Lee JM.

Eur J Hum Genet. 2017 Aug 23. doi: 10.1038/ejhg.2017.125. [Epub ahead of print]

The Effect of Music Therapy in Patients with Huntington's Disease: A Randomized Controlled Trial.

van Bruggen-Rufi MC, Vink AC, Wolterbeek R, Achterberg WP, Roos RA.

J Huntingtons Dis. 2017 Mar 15. doi: 10.3233/JHD-160229. [Epub ahead of print]

Amino acid substitution equivalent to human chorea-acanthocytosis I2771R in yeast Vps13 protein affects its binding to phosphatidylinositol 3-phosphate.

Rzepnikowska W, Flis K, Kaminska J, Grynberg M, Urbanek A, Ayscough KR, Zoladek T.

Hum Mol Genet. 2017 Mar 1. doi: 10.1093/hmg/ddx054. [Epub ahead of print]

Evolving Motivations: Patients' and Caregivers' Perceptions About Seeking Myotonic Dystrophy (DM1) and Huntington's Disease Care.

LaDonna KA, Watling CJ, Ray SL, Piechowicz C, Venance SL.

Qual Health Res. 2017 Sep;27(11):1727-1737. doi: 10.1177/1049732317711901. Epub 2017 Jun 19.

Corrigendum: Motivational, proteostatic and transcriptional deficits precede synapse loss, gliosis and neurodegeneration in the B6.Htt(Q111/+) model of Huntington's disease.

Bragg RM, Coffey SR, Weston RM, Ament SA, Cantle JP, Minnig S, Funk CC, Shuttleworth DD, Woods EL, Sullivan BR, Jones L, Glickenhaus A, Anderson JS, Anderson MD, Dunnett SB, Wheeler VC, MacDonald ME,

Sci Rep. 2017 Mar 28;7:44960. doi: 10.1038/srep44960. No abstract available.

HDNetDB: A Molecular Interaction Database for Network-Oriented Investigations into Huntington's Disease.

Kalathur RKR, Pedro Pinto J, Sahoo B, Chaurasia G, Futschik ME.

Sci Rep. 2017 Jul 12;7(1):5216. doi: 10.1038/s41598-017-05224-0.

Is there a place for human fetal-derived stem cells for cell replacement therapy in Huntington's disease?

Precious SV, Zietlow R, Dunnett SB, Kelly CM, Rosser AE.

Neurochem Int. 2017 Jan 27. pii: S0197-0186(17)30011-6. doi: 10.1016/j.neuint.2017.01.016. [Epub ahead of print] Review.

White matter predicts functional connectivity in premanifest Huntington's disease.

McColgan P, Gregory S, Razi A, Seunarine KK, Gargouri F, Durr A, Roos RA, Leavitt BR, Scahill RI, Clark CA, Tabrizi SJ, Rees G; and the Track On‐HD Investigators., Coleman A, Decolongon J, Fan M, Petk

Ann Clin Transl Neurol. 2017 Jan 16;4(2):106-118. doi: 10.1002/acn3.384.

Regenerative medicine in Huntington's disease: strengths and weaknesses of preclinical studies.

Tartaglione AM, Popoli P, Calamandrei G.

Neurosci Biobehav Rev. 2017 Feb 18. pii: S0149-7634(16)30778-3. doi: 10.1016/j.neubiorev.2017.02.017. [Epub ahead of print] Review.

Transcriptional profiles for distinct aggregation states of mutant Huntingtin exon 1 protein unmask new Huntington's disease pathways.

Moily NS, Ormsby AR, Stojilovic A, Ramdzan YM, Diesch J, Hannan RD, Zajac MS, Hannan AJ, Oshlack A, Hatters DM.

Mol Cell Neurosci. 2017 Jul 23;83:103-112. doi: 10.1016/j.mcn.2017.07.004. [Epub ahead of print]

Perturbations in the p53/miR-34a/SIRT1 pathway in the R6/2 Huntington's disease model.

Reynolds RH, Petersen MH, Willert CW, Heinrich M, Nymann N, Dall M, Treebak JT, Björkqvist M, Silahtaroglu A, Hasholt L, Nørremølle A.

Mol Cell Neurosci. 2017 Dec 28. pii: S1044-7431(17)30099-4. doi: 10.1016/j.mcn.2017.12.009. [Epub ahead of print]

Abnormal degradation of the neuronal stress-protective transcription factor HSF1 in Huntington's disease.

Gomez-Pastor R, Burchfiel ET, Neef DW, Jaeger AM, Cabiscol E, McKinstry SU, Doss A, Aballay A, Lo DC, Akimov SS, Ross CA, Eroglu C, Thiele DJ.

Nat Commun. 2017 Feb 13;8:14405. doi: 10.1038/ncomms14405.

Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells.

Xu X, Tay Y, Sim B, Yoon SI, Huang Y, Ooi J, Utami KH, Ziaei A, Ng B, Radulescu C, Low D, Ng AY, Loh M, Venkatesh B, Ginhoux F, Augustine GJ, Pouladi MA.

Stem Cell Reports. 2017 Feb 21. pii: S2213-6711(17)30038-3. doi: 10.1016/j.stemcr.2017.01.022. [Epub ahead of print]

Exercise effects in Huntington disease.

Frese S, Petersen JA, Ligon-Auer M, Mueller SM, Mihaylova V, Gehrig SM, Kana V, Rushing EJ, Unterburger E, Kägi G, Burgunder JM, Toigo M, Jung HH.

J Neurol. 2017 Jan;264(1):32-39. doi: 10.1007/s00415-016-8310-1.